Literature DB >> 35348584

Changes in circulating microRNAs-99/100 and reductions of visceral and ectopic fat depots in response to lifestyle interventions: the CENTRAL trial.

Yoriko Heianza1, Knut Krohn2, Qiaochu Xue1, Anat Yaskolka Meir3, Stefanie Ziesche4, Uta Ceglarek5, Matthias Blüher4,6, Maria Keller4,6, Peter Kovacs4, Iris Shai3,7, Lu Qi1,7.   

Abstract

BACKGROUND: MicroRNAs (miRNAs) are short noncoding RNAs and important posttranscriptional regulators of gene expression. Adipose tissue is a major source of circulating miRNAs; adipose-related circulating miRNAs may regulate body fat distribution and glucose metabolism.
OBJECTIVES: We investigated how changes in adipose-related circulating microRNAs-99/100 (miR-99/100) in response to lifestyle interventions were associated with improved body fat distribution and reductions of diabetogenic ectopic fat depots among adults with abdominal obesity.
METHODS: This study included adults with abdominal obesity from an 18-mo diet and physical activity intervention trial. Circulating miR-99a-5p, miR-99b-5p, and miR-100-5p were measured at baseline and 18 mo; changes in these miRNAs in response to the interventions were evaluated. The primary outcomes were changes in abdominal adipose tissue [visceral (VAT), deep subcutaneous (DSAT), and superficial subcutaneous (SSAT) adipose tissue; cm2] (n = 144). The secondary outcomes were changes in ectopic fat accumulation in the liver (n = 141) and pancreas (n = 143).
RESULTS: Greater decreases in miR-100-5p were associated with more reductions of VAT (β ± SE per 1-SD decrease: -9.63 ± 3.13 cm2; P = 0.0025), DSAT (β ± SE: -5.48 ± 2.36 cm2; P = 0.0218), SSAT (β ± SE: -4.64 ± 1.68 cm2; P = 0.0067), and intrahepatic fat percentage (β ± SE: -1.54% ± 0.49%; P = 0.0023) after the interventions. Similarly, participants with greater decrease in miR-99a-5p had larger 18-mo reductions of VAT (β ± SE: -10.12 ± 3.31 cm2 per 1-SD decrease; P = 0.0027) and intrahepatic fat percentage (β ± SE: -1.28% ± 0.52%; P = 0.015). Further, decreases in circulating miR-99b-5p (β ± SE: per 1-SD decrease: -0.44% ± 0.21%; P = 0.038) and miR-100-5p (β ± SE: -0.50% ± 0.23%; P = 0.033) were associated with a decrease in pancreatic fat percentage, as well as improved glucose metabolism and insulin secretion at 18 mo.
CONCLUSIONS: Decreases in circulating miR-99-5p/100-5p expression induced by lifestyle interventions were related to improved body fat distribution and ectopic fat accumulation. Our study suggests that changes in circulating adipose-related miR-99-5p/100-5p may be linked to reducing diabetogenic fat depots in patients with abdominal obesity.This trial was registered at clinicaltrials.gov as NCT01530724.
© The Author(s) 2022. Published by Oxford University Press on behalf of the American Society for Nutrition.

Entities:  

Keywords:  body fat distribution; ectopic fat; insulin sensitivity; lifestyle interventions; microRNAs

Mesh:

Substances:

Year:  2022        PMID: 35348584      PMCID: PMC9257465          DOI: 10.1093/ajcn/nqac070

Source DB:  PubMed          Journal:  Am J Clin Nutr        ISSN: 0002-9165            Impact factor:   8.472


  42 in total

Review 1.  Circulating microRNAs: novel biomarkers and extracellular communicators in cardiovascular disease?

Authors:  Esther E Creemers; Anke J Tijsen; Yigal M Pinto
Journal:  Circ Res       Date:  2012-02-03       Impact factor: 17.367

2.  Altered miRNA processing disrupts brown/white adipocyte determination and associates with lipodystrophy.

Authors:  Marcelo A Mori; Thomas Thomou; Jeremie Boucher; Kevin Y Lee; Susanna Lallukka; Jason K Kim; Martin Torriani; Hannele Yki-Järvinen; Steven K Grinspoon; Aaron M Cypess; C Ronald Kahn
Journal:  J Clin Invest       Date:  2014-07-01       Impact factor: 14.808

Review 3.  Extracellular miRNAs: From Biomarkers to Mediators of Physiology and Disease.

Authors:  Marcelo A Mori; Raissa G Ludwig; Ruben Garcia-Martin; Bruna B Brandão; C Ronald Kahn
Journal:  Cell Metab       Date:  2019-08-22       Impact factor: 27.287

4.  Ectopic fat storage in the pancreas, liver, and abdominal fat depots: impact on β-cell function in individuals with impaired glucose metabolism.

Authors:  N J van der Zijl; G H Goossens; C C M Moors; D H van Raalte; M H A Muskiet; P J W Pouwels; E E Blaak; M Diamant
Journal:  J Clin Endocrinol Metab       Date:  2010-11-17       Impact factor: 5.958

5.  MiRNA expression profile of human subcutaneous adipose and during adipocyte differentiation.

Authors:  Francisco J Ortega; José M Moreno-Navarrete; Gerard Pardo; Monica Sabater; Manuela Hummel; Anna Ferrer; Jose I Rodriguez-Hermosa; Bartomeu Ruiz; Wifredo Ricart; Belen Peral; José M Fernández-Real
Journal:  PLoS One       Date:  2010-02-02       Impact factor: 3.240

Review 6.  Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes.

Authors:  Zobair M Younossi; Aaron B Koenig; Dinan Abdelatif; Yousef Fazel; Linda Henry; Mark Wymer
Journal:  Hepatology       Date:  2016-02-22       Impact factor: 17.425

Review 7.  MicroRNAs: target recognition and regulatory functions.

Authors:  David P Bartel
Journal:  Cell       Date:  2009-01-23       Impact factor: 41.582

8.  MicroRNA-99a mimics inhibit M1 macrophage phenotype and adipose tissue inflammation by targeting TNFα.

Authors:  Anant Jaiswal; Sukka Santosh Reddy; Mohita Maurya; Preeti Maurya; Manoj Kumar Barthwal
Journal:  Cell Mol Immunol       Date:  2018-05-30       Impact factor: 11.530

9.  Circulating MiRNAs of 'Asian Indian Phenotype' Identified in Subjects with Impaired Glucose Tolerance and Patients with Type 2 Diabetes.

Authors:  Paramasivam Prabu; Sophie Rome; Chandrakumar Sathishkumar; Sankaramoorthy Aravind; Balakumar Mahalingam; Coimbatore Subramanian Shanthirani; Caroline Gastebois; Audrey Villard; Viswanathan Mohan; Muthuswamy Balasubramanyam
Journal:  PLoS One       Date:  2015-05-28       Impact factor: 3.240

Review 10.  FGF21: An Emerging Therapeutic Target for Non-Alcoholic Steatohepatitis and Related Metabolic Diseases.

Authors:  Erik J Tillman; Tim Rolph
Journal:  Front Endocrinol (Lausanne)       Date:  2020-12-14       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.